Positive News SentimentPositive NewsNASDAQ:PMVP PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis $1.69 +0.04 (+2.42%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.65▼$1.7350-Day Range$1.47▼$2.2152-Week Range$1.18▼$9.72Volume388,809 shsAverage Volume516,073 shsMarket Capitalization$86.94 millionP/E RatioN/ADividend YieldN/APrice Target$5.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get PMV Pharmaceuticals alerts: Email Address PMV Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside240.2% Upside$5.75 Price TargetShort InterestHealthy2.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.57Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.36) to ($1.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.50 out of 5 starsMedical Sector295th out of 936 stocksPharmaceutical Preparations Industry134th out of 436 stocks 3.6 Analyst's Opinion Consensus RatingPMV Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePMV Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about PMV Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.66% of the float of PMV Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPMV Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PMV Pharmaceuticals has recently decreased by 48.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPMV Pharmaceuticals does not currently pay a dividend.Dividend GrowthPMV Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PMVP. Previous Next 3.7 News and Social Media Coverage News SentimentPMV Pharmaceuticals has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for PMV Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for PMVP on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added PMV Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PMV Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.60% of the stock of PMV Pharmaceuticals is held by insiders.Percentage Held by Institutions90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PMV Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.36) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PMV Pharmaceuticals is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PMV Pharmaceuticals is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPMV Pharmaceuticals has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about PMV Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About PMV Pharmaceuticals Stock (NASDAQ:PMVP)PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Read More PMVP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMVP Stock News HeadlinesMay 29, 2024 | globenewswire.comFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorMay 29, 2024 | businesswire.comFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PMV Pharmaceuticals (PMVP) and Phathom Pharmaceuticals (PHAT)May 14, 2024 | msn.comCraig-Hallum Initiates Coverage of PMV Pharmaceuticals (PMVP) with Buy RecommendationMay 9, 2024 | globenewswire.comPMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate HighlightsApril 19, 2024 | finance.yahoo.comPMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth PlansApril 18, 2024 | msn.comPMV Pharmaceuticals (PMVP) Price Target Increased by 45.83% to 8.93July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.March 27, 2024 | globenewswire.comPMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsMarch 18, 2024 | finance.yahoo.comPMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s CancerMarch 18, 2024 | globenewswire.comPMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's CancerMarch 16, 2024 | finance.yahoo.comPMVP Apr 2024 5.000 callMarch 3, 2024 | finanznachrichten.dePMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsMarch 1, 2024 | markets.businessinsider.comOppenheimer Keeps Their Hold Rating on PMV Pharmaceuticals (PMVP)March 1, 2024 | finance.yahoo.comPMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial ResultsMarch 1, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on PMV Pharmaceuticals (PMVP)February 29, 2024 | globenewswire.comPMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsSee More Headlines Receive PMVP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PMVP CUSIPN/A CIK1699382 Webwww.pmvpharma.com Phone609-642-6670FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$5.75 High Stock Price Target$7.00 Low Stock Price Target$5.00 Potential Upside/Downside+235.3%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.14% Return on Assets-26.24% Debt Debt-to-Equity RatioN/A Current Ratio16.79 Quick Ratio16.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book0.39Miscellaneous Outstanding Shares51,443,000Free Float47,533,000Market Cap$88.22 million OptionableOptionable Beta1.53 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. David H. Mack Ph.D. (Age 62)Co-Founder, CEO, President & Director Comp: $881.08kDr. Arnold J. Levine Ph.D. (Age 84)Co-Founder, Director & Member of Scientific Advisory Board Comp: $140kDr. Deepika Jalota Pharm.D. (Age 47)Chief Development Officer Comp: $593.9kDr. Thomas E. Shenk Ph.D. (Age 77)Co-Founder & Member of Scientific Advisory Board Mr. Michael Carulli (Age 50)Chief Financial Officer Mr. Robert Ticktin (Age 62)General Counsel, Head of Operations & Company Secretary Mr. Tim SmithSenior VP & Head of Corporate Development and Investor RelationsMs. Crystal ZuckermanVice President of Human ResourcesDr. Binh Vu Ph.D.Senior VP of Drug Discovery & CMCDr. Marc Fellous M.D.Senior VP and Head of Clinical Development & Medical AffairsMore ExecutivesKey CompetitorsAtea PharmaceuticalsNASDAQ:AVIRADC TherapeuticsNYSE:ADCTSutro BiopharmaNASDAQ:STROEnanta PharmaceuticalsNASDAQ:ENTAScilexNASDAQ:SCLXView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 189,214 shares on 7/18/2024Ownership: 0.505%Opaleye Management Inc.Bought 471,481 shares on 5/29/2024Ownership: 0.917%Jacobs Levy Equity Management Inc.Bought 397,062 shares on 5/16/2024Ownership: 1.607%Price T Rowe Associates Inc. MDBought 17,858 shares on 5/15/2024Ownership: 0.083%Public Employees Retirement System of OhioBought 14,457 shares on 5/15/2024Ownership: 0.044%View All Insider TransactionsView All Institutional Transactions PMVP Stock Analysis - Frequently Asked Questions How have PMVP shares performed this year? PMV Pharmaceuticals' stock was trading at $3.10 at the beginning of 2024. Since then, PMVP shares have decreased by 45.5% and is now trading at $1.69. View the best growth stocks for 2024 here. How were PMV Pharmaceuticals' earnings last quarter? PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. When did PMV Pharmaceuticals IPO? PMV Pharmaceuticals (PMVP) raised $126 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO. Who are PMV Pharmaceuticals' major shareholders? Top institutional investors of PMV Pharmaceuticals include Assenagon Asset Management S.A. (0.51%). Insiders that own company stock include Deepika Jalota, Winston Kung, Orbimed Advisors Llc, Arnold J Levine, Leila Alland and Thilo Schroeder. View institutional ownership trends. How do I buy shares of PMV Pharmaceuticals? Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of PMV Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that PMV Pharmaceuticals investors own include Vical (VICL), Arista Networks (ANET), Apollo Medical (AMEH), Advanced Micro Devices (AMD), Ambarella (AMBA), Alexion Pharmaceuticals (ALXN) and Akoustis Technologies (AKTS). This page (NASDAQ:PMVP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMVP Stock Alerts